Evaluating topical minoxidil for treating acne vulgaris
A Phase I/II Clinical Study of Topical Minoxidil in Acne Vulgaris
This study is testing if a topical treatment called minoxidil can safely help adults with mild to moderate acne clear up their skin.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 26 (estimated) |
| Ages | 20 Years to 50 Years |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Locations | 1 site (Taoyuan) |
| Trial ID | NCT06108193 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to assess the toxicity and efficacy of topical minoxidil in patients with acne vulgaris. Participants aged 20 to 50 with mild to moderate acne will undergo baseline blood and urine tests, and their acne lesions will be monitored over a 14-day period. The primary objective is to evaluate the safety of minoxidil, while secondary objectives include measuring the response rate and time to resolution of acne lesions. Daily photographic documentation will be used to track treatment efficacy.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 20 to 50 with mild to moderate acne vulgaris.
Not a fit: Patients who are pregnant, breastfeeding, or have a known allergy to minoxidil will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new topical option for patients suffering from acne vulgaris.
How similar studies have performed: While topical minoxidil is primarily known for hair loss treatment, its application in acne vulgaris is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Gender: both 2. Age limit: 20\~50 year/old 3. Acne vulgaris: mild to moderate degree (Investigator's Global Assessment Scale:2\~3) Exclusion Criteria: 1. pregnant or breast feeding woman 2. allergic to minoxidil or any ingredient of minoxidil solution including alcohol and propylene glycol 3. deny to discontinue topical therapy of acne more than 7 days before starting treatment 4. deny to discontinue systemic therapy of acne more than 28 days before starting treatment 5. alopecia under or ever using minoxidil, known androgen-AR pathway blocker 6. using shampoo containing minoxidil component in 28 days before starting treatment 7. irregular menstruation of known case of polycystic ovarian syndrome 8. Have had a facial procedure 2 weeks before the study start 9. using any oral contraceptives that have a specific anti-androgenic action 12 weeks before the study start
Where this trial is running
Taoyuan
- Linkou Chang Gung Memorial Hospital — Taoyuan, Taiwan (Recruiting)
Study contacts
- Principal investigator: Cheng-Lung Hsu, Profesor — Chang Gung Memorial Hospital
- Study coordinator: Cheng-Lung Hsu, Profesor
- Email: hsu2221@cgmh.org.tw
- Phone: (886)33281200
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.